Factors associated with the evolution of the viral load in individuals with HIV infection

International Journal of Antimicrobial Agents

Volumn 21, Issue 5, 2003, Pages 478-483

  Ortega, M ^a,c   Eiros, J M ^b   Labayru, C ^a   Hernandez B ^a   Bou, G ^b   De Lejarazu, R Ortiz ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^b HOSPITAL JUAN CANALEJO   (Spain)

^c NONE   (Spain)

Author keywords

Basal VL status; Evolution; Gender; HIV 1 viral load

Indexed keywords

ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; EVOLUTION; FEMALE; FOLLOW UP; GENDER; HEALTH STATUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; IMMUNOSURVEILLANCE; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; NEWBORN; PATIENT MONITORING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIREMIA; VIROLOGY; VIRUS DETECTION; VIRUS IDENTIFICATION; VIRUS LOAD;

EID: 0242501547     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(03)00040-2     Document Type: Article

References (26)

1. Miró J.M., Antela A., Arrizabalaga J., Clotet B., et al. Recomendaciones de GESIDA/Plan Nacional sobre el SIDA respecto al tratamiento antirretrovírico en pacientes adultos infectados por el Virus de la Inmunodeficiencia Humana en el año 2000 (I). Enferm. Infect. Microbiol. Clin. 18:2000;329-351.
2. García F., Romeu J., Grau I., et al. A randomized study comparing triple versus double antiretroviral therapy or no treatment HIV-1 infected patients in very early stage disease: the Spanish Earth-1 study. AIDS. 13:1999;2377-2388.
3. Fauci AS, Bartlett JG, Goosby EP, Kates J. dirs. Directrices para el empleo de fármacos antirretrovirales en adultos y adolescentes VIH+. Elaboradas por el Departamento de Salud y Servicios Humanos de Estados Unidos (DHHS) y la Fundación Henry J Kaiser Family, edición española. Traducido por cortesía de DuPont Pharma. Febrero, 2001.
4. Palella F.J., Delaney K.M., Moorman A.C., et al. Declining morbility and mortality among patients with advanced human immunodeficiency virus infection. New Engl. J. Med. 338:1998;853-860.
5. Mocroft A., Vella S., Benfield T.L., et al. Changing patters of mortality across Europe in patients infected with HIV-1. Lancet. 352:1998;1730-1752.
6. Paterson D.L., Swindells S., Mohr J., et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. 133:2000;21-30.
7. Zhang L., Ramratnam B., Tenner-Racz K., et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. New Engl. J. Med. 340:1999;1605-1613.
8. D'Aquila R., Walker B. Exploring the benefits and limits of highly active antiretroviral therapy. J. Am. Med. Assoc. 282:1999;1668-1669.
9. Pomerantz R. Residual HIV-1 disease in the era of highly active antiretroviral therapy. New Engl. J. Med. 340:1999;1672-1674.
10. Furtado M.R., Callaway D.S., Phair J.P., et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. New Engl. J. Med. 340:1999;1614-1622.
11. Laurence J. Antiretroviral therapy in HIV/SIDA: update from San Francisco. AIDS Read. 10:2000;133-134.
12. Sterling T.R., Vlahov D., Astemborski J., Hoover D.R., Margolick J.B., Quinn T.C. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. New Engl. J. Med. 344:2001;720-725.
13. Lyles C.M., Dorrucci M., Vlahov D., et al. Longitudinal human immunodeficiency virus type 1 load in the Italian seroconversion study: correlates and temporal trends of viral load. J. Infect. Dis. 180:1999;1018-1024.
14. Moore A.L., Mocroft A., Madge S., et al. Gender differences in virologic response to treatment in an HIV-positive population: a cohort study. J. Acquired Immune Defic. Syndr. 26:2001;159-163.
15. Hewitt R.G., Parsa N., Gugino L. Women's health. The role of gender in HIV progression. AIDS Read. 11:2001;29-33.
16. Rezza G., Lepri A.C., d'Arminio Monforte A., et al. Plasma viral load concentrations in women and men from different exposure categories and with kwon duration of HIV infection. ICONA Study Group. J. Acquired Immune Defic. Syndr. 25:2000;56-62.
17. Meynard J.L., Guiguet M., Rachline A., et al. Predictive factors of virologic response to antiretroviral treatment with a protease inhibitor in HIV infection. Presse Med. 30:2001;5-10.
18. Rizzardi G.P., Tambussi G., Bart P.A., Chapuis A.G., Lazzarin A., Pantaleo G. Virological and immunological responses to HAART in asymtomatic therapy-naive HIV-1-infected subjects according to CD4 cell count. AIDS. 14:2000;2257-2263.
19. Bart P.A., Rizzardi G.P., Tambussi G., et al. Immunological and virological responses in HIV-1 infected adults at early stage of established infection treated with highly active antiretroviral therapy. AIDS. 14:2000;1887-1897.
20. Roussanov B.V., Taylor J.M.G., Giorgi J.V. Calculation and use of an HIV-1 disease progression score. AIDS. 14:2000;2715-2722.
21. Grabar S., Le Moing V., Goujard C., et al. Clinical outcome of patients with HIV-1 infection according to immunological and virological response after 6 months of highly active antiretroviral therapy. Ann. Intern. Med. 133:2000;401-410.
22. Popper S.J., Sarr A.D., Travers K.U. Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. J. Infect. Dis. 180:1999;1116-1121.
23. Ikuta K., Suzuki S., Horikoshi H., Mukai T., Luftig R.B. Positive and negative aspect of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis. Microbiol. Mol. Biol. Rev. 64:2000;725-745.
24. Chaisson R.E., Keruly J.C., Moore R.D. Association of initial CD4 cell count and viral load with response to highly active antiretroviral therapy. J. Am. Med. Assoc. 284:2000;3128-3129.
25. Powderly W.G., Saag M.S., Chapman S., Yu G., Quart B., Clendeninn N.J. Predictors of optimal virological response to potent antiretroviral therapy. AIDS. 13:1999;1873-1880.
26. Paterson D, Swindells S, Mohr J, et al. How much adherence is enough? A prospective study of adherence to protease inhibitor therapy using MEMSCaps. From: 6th Conference on Retrovirus and Opportunistic Infections. Chicago, III, 31 January-4 February 1999. Abstract 92.